Latest Ucb S A (UCBJF) Headlines UCB Misses Earnings Ests,

New Post Public Reply Private Reply Replies (0) Message Board

Mar 11, 2014 at 10:49 PM

Latest Ucb S A (UCBJF) Headlines

UCB Misses Earnings Ests, Revs In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 12:32PM CST
UCB reported 2013 earnings per share of $2.56, missed the Zacks Consensus Estimate of $2.84.

UCB : CONVENING NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
Thomson Reuters ONE - Fri Feb 21, 2:01AM CST
The shareholders are invited to attend the Extraordinary General Meeting which will be held on Monday, 24 March 2014, at 09:00 am CET at the registered office of UCB SA/NV, Allee de la Recherche 60 - 1070 Brussels, for the purpose of considering the items shown on the agenda set out below.

Worldwide Nanomedicine Market Report 2013-2019: Neurology, Cardiovascular, Anti-inflammatory, Anti-infective & Oncology Applications
M2 - Wed Feb 19, 9:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4bpxtn/nanomedicine) has announced the addition of the "Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report includes market estimations for the nanomedicine market for the forecast period 2013 - 2019. The market size is represented in terms of USD billion and the market estimates and forecasts are calculated, considering 2012 as the base year. Moreover, market trends and recent developments have been kept into account while forecasting market growth and revenue for the period 2013 - 2019. The overall nanomedicine market is segmented on the basis of application and geography and the market estimations for each of these segments, in terms of USD billion, is provided in this report. The nanomedicine market, by applications is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other markets. The nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and rest of the world. The global trends such as drivers, restraints and opportunities of the global nanomedicine market is detailed in the market overview chapter of this report., with a view on impact of these factors on market growth along the course of the forecast period. The chapter on competitive landscape consists of heat map analysis of the key players operating in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global nanomedicine market is categorized into the following segments: - Neurology - Cardiovascular - Anti-Inflammatory - Anti-Infectives - Oncology - Others Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Nanomedicine Market Overview Chapter 4 Global Nanomedicine Market, by Applications Chapter 5 Global Nanomedicine Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Abbott Laboratories - Celgene Corporation - CombiMatrix Corporation - GE Healthcare - Johnson & Johnson - Mallinckrodt plc. - Merck & Company Inc. - Nanosphere, Inc. - Pfizer Inc. - Sigma-Tau Pharmaceuticals Inc. - Teva Pharmaceutical Industries Ltd. - UCB SA For more information visit http://www.researchandmarkets.com/research/4b...nomedicine

CHMP Positive on Roche's RoActemra's Subcutaneous Formulation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 23, 9:50AM CST
Roche recently received positive news when the Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion on the subcutaneous formulation of rheumatoid arthritis (RA) drug RoActemra.

Good News for Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 22, 12:30PM CDT
Roche received encouraging news when the U.S. Food and Drug Administration (FDA) approved a subcutaneous (SC) formulation of its rheumatoid arthritis (RA) drug Actemra

Loss Narrows at Immunomedics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 26, 8:54AM CDT
Immunomedics reported fourth quarter 2013 loss of 9 cents per share.

Good News for RedHill Biopharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 23, 3:10PM CDT
Good news flowed in at RedHill Biopharma when the company received a positive feedback on its RHB-104.

Another Generic Launch at Mylan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 16, 9:50AM CDT
Mylan launched its generic version of Abbott Labs' Trilipix.

New Data on UCB's Cimzia - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 14, 2:48PM CDT
UCB presented new data from the RAPID-PsA study and RAPID-axSpA study on Cimzia at the European League Against Rheumatism (EULAR) Congress.

Update on UCB Lupus Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 13, 8:40PM CDT
UCB recently presented new data on its lupus candidate, epratuzumab, from an open-label extension study of the EMBLEM phase IIb study

Label Expansion for Roche's RoActemra - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 12, 9:10PM CDT
Roche announced that it obtained European Medicines Agency (EMA) approval for the label expansion of its rheumatoid arthritis (RA) drug RoActemra.

Data on UCB's Neupro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 22, 8:55PM CDT
UCB presented data from a study showing the effect of Neupro on cardiovascular measures in patients with restless legs syndrome.

Nektar Posts Wider Loss, Maintains View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 15, 10:26AM CDT
Nektar reported a loss of 48 cents per share in the first quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 41 cents.

Questcor Misses on Earnings, Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 03, 1:16PM CDT
Questcor reported first quarter 2013 adjusted earnings per share of 66 cents, up 13.8% from the year-ago period

Valeant Beats Earnings, Misses Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 03, 12:05PM CDT
Valeant Pharmaceuticals' (VRX) first quarter 2013 earnings of $1.27 (excluding special items but including stock-based compensation expense) were short of the Zacks Consensus Estimate by a penny but were up from the year-ago earnings of 1.08 per share

Ucb S A (UCBJF) Stock Research Links

UCBJF Board Company Profile Buy Rating Time & Sales News Filings Financials

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SeaWorld Rings in Holidays with All-New Festivities

Holiday Transformation at SeaWorld's Parks The holiday spirit isn't something you purchase—it’s an experience. And boy, SeaWorld seems to get this right. As the chill of late October settles in, SeaWorld parks across Orlando, San Diego, and San Antonio start dressing up for the holiday season, morphing into a spectacle of lights and festive joy. For anyone who’s...

Human Judgment Crucial Amid AI Growth in Courts

AI in the Justice System: Balancing Potential and Pitfalls You know, when it comes to upholding justice, there's a line between what machines can handle and what only a human can bring to the gavel. Chief Justice Sundaresh Menon of Singapore threw the spotlight on this at an event in Brisbane, hammering home the need for good ole human intuition in the courtroom even as...

One Stop Swap Empowers Retirees in Resale Boom

Tapping into the Retirement Market There's a shake-up brewing in the resale economy, and it’s got 'retirement' written all over it. Thanks to One Stop Swap's fresh Second Act initiative, there's a move to transform retirees from passive consumers into active entrepreneurs. It's not just about letting folks clear out their basements; it's about placing a bet on the...

Victory Gala Honors Heroes, Raises Over $500K

A Night Celebrating Service and Sacrifice You know, in times like these, it’s refreshing to see events that focus on giving back rather than taking everything to the bank. Victory Home Remodeling, along with its nonprofit arm, the Victory Foundation, recently hosted their second annual gala in Woodland Park, New Jersey to give some much-needed limelight to those who put...

A Fresh Perspective on Asakusa's Cultural Wonders

Unveiling the Hidden Layers of Asakusa When most tourists wander through Tokyo's Asakusa district, they rarely scratch beneath the surface of what truly animates this historic area. It’s more than just the Sens?-ji Temple or the bustling Nakamise shopping street. We're talking about the beating heart of Asakusa’s living cultural heritage—the very artisans and...

Famous Brands Slashes Fees to Boost Franchise Growth

Throwing a Sweet Deal for New Franchise Owners Talk about a move that’s got the industry buzzing—Famous Brands International, the folks behind Mrs. Fields and TCBY, just rolled out a tantalizing offer you don’t see every day. They’re slashing franchise fees and royalties by half for new franchisees who jump onboard before the ball drops on 2026. I’ll tell ya,...

Trade Secret Insurance Unveiled: A New Frontier

Unseen Assets: The Untapped Wealth of Trade Secrets Ever pondered the real goldmine buried in your company's files? Mary Guzman certainly has, and she's cooked up a way to protect it. Guzman, the brain behind Crown Jewel Insurance, aims to shine a spotlight on those 'hidden gem' trade secrets that businesses often overlook. As the world increasingly turns intangible, it's...

FMC Corporation's Q3 2026: Tough Quarter, Dim Outlook

FMC's Challenging Third Quarter Let's cut through the red tape right away—FMC Corporation just rolled out its Q3 2026 results, and boy, it wasn't pretty. Revenue plummeted to $106 million—a staggering drop from the $542 million of the same quarter last year. If you're wondering how such a bruising came about, you can thank the hefty commercial actions they pulled out...

Palmetto Publishing's M&A Guide Aims to Boost Home Services

Palmetto's New Release: Mergers & Acquisitions Focus Man, Palmetto Publishing just dropped a bombshell for home services aficionados with their latest M&A guide. Now, if you’re like me, swimming in stocks and always looking for that next big exit play, this one’s tailor-made for you. Mergers and acquisitions might not sound as flashy as the tech darlings or...

HR HealthCare Foundation: New Chapter of Giving

HR HealthCare Reaffirms Commitment Through New Foundation The corporate world didn't see this one coming. On October 29, 2026, HR HealthCare, a stalwart in the healthcare products arena, has decided to double down on its benevolent side by establishing the HR HealthCare Foundation. It ain't just about selling widgets anymore; it's about making a genuine impact outside the...